Saturday 17 October 2026 Export LONA’s income statement to Excel — free account

LeonaBio, Inc.

In the quarter to June 2026, EPS grew 55.6% and free cash flow fell 142.3%, each against the same quarter a year earlier.

5.20 0.09 −1.70%

Follow LONA

Alert me

Market cap: $49.8M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	5	—	5	—	—	—	—	—	—	—

Insider Ownership 73.15%

Capital & Financial Ratios $m

Market Cap 49.84

Revenue —

Net Income (141.45)

Free Cash Flow (61.93)

Net Debt (51.07)

Current Ratio 7.01

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 3.67

Past 5Y EPS Growth —

This Y EPS Growth 88.52%

Next Y EPS Growth 17.46%

Next Y revenue growth —

Next 5Y EPS Growth 58.52%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 93.68%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	147	51	88	51
Receivables	2	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	155	55	89	55

	2023	2024	2025	Q'26
Payables	0	0	5	2
ST’ Debt	—	—	—	—
Other	—	—	37	—
	29	13	48	8

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(36.74%)	(50.93%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(17)	—	—	—
’25	(15)	(7)	(5)	(19)	(46)
’24	(26)	(22)	(23)	(26)	(97)
’23	(26)	(24)	(24)	(26)	(101)
’22	(17)	(19)	(22)	(16)	(72)
’21	(7)	(7)	(10)	(18)	(43)
’20	(1)	(3)	(9)	(11)	(24)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(17)	—	—	—
’25	(15)	(7)	(5)	(19)	(46)
’24	(26)	(22)	(23)	(26)	(97)
’23	(26)	(24)	(24)	(26)	(101)
’22	(17)	(19)	(22)	(16)	(74)
’21	(8)	(7)	(10)	(19)	(45)
’20	(1)	(3)	(9)	(13)	(26)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.73)	(0.80)	—	—	—
’25	(2.30)	(1.80)	(1.68)	(18.90)	(24.70)
’24	(6.90)	(7.00)	(7.50)	(3.90)	(25.20)
’23	(7.30)	(7.80)	(8.70)	(7.10)	(30.90)
’22	(5.60)	(6.50)	(5.30)	(7.90)	(25.30)
’21	(2.50)	(3.80)	(4.20)	(3.70)	(14.90)
’20	(4.82)	(4.83)	(11.20)	(2.40)	(16.70)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	157.90	88.80	25.30	13.30	4.12	2.20	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	347.90	342.50	142.20	44.10	42.98	8.36
People
People	Employees	—	—	—	—	22	35	64	67	26	19
	Revenue/emp, $m	—	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	0.00	0.00	0.00	—	—	—
	EBT	—	—	(5)	(5)	(20)	(55)	(96)	(118)	(97)	(106)
	EBT margin, %	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	(5)	(5)	(20)	(55)	(96)	(118)	(97)	(106)
	Depreciation	—	—	0	0	0	1	0	0	0	1
Per share, $
Per share, $	Revenue	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	(14.69)	(14.47)	(16.70)	(14.90)	(25.30)	(30.90)	(25.20)	(24.70)
	Cash flow	—	—	(12.92)	(10.41)	(20.15)	(11.67)	(19.21)	(26.50)	(25.25)	(10.69)
	Capex	—	—	0.00	0.00	(1.94)	(0.43)	(0.30)	(0.08)	(0.01)	0.00
	Free cash flow	—	—	(12.92)	(10.41)	(22.09)	(12.10)	(19.51)	(26.58)	(25.26)	(10.69)
	Book value	—	—	6.24	(7.49)	229.20	86.97	62.32	34.24	11.65	6.50
	Shares, m	—	—	0	0	1	4	4	4	4	4
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	(4)	(4)	(24)	(43)	(72)	(101)	(97)	(46)
	Capex	—	—	—	—	(2)	(2)	(1)	0	0	—
	Free cash flow	—	—	(4)	(4)	(26)	(45)	(74)	(101)	(97)	(46)
Balance, $m
Balance, $m	Working capital	—	—	4	1	188	252	186	126	42	42
	Total debt	—	—	1	2	1	2	2	—	—	—
	Net debt	—	—	(4)	(1)	(185)	(254)	(200)	(147)	(51)	(88)
	Shareholders’ equity	—	—	2	(3)	274	321	235	130	45	28
Returns, %
Returns, %	ROA	—	—	(206.65)	(144.93)	(14.16)	(17.94)	(32.41)	(56.25)	(88.52)	(139.94)
	ROIC	—	—	0.00	0.00	(13.95)	(59.43)	(186.85)	0.00	0.00	0.00
	ROE	—	—	29.45	29.82	(15.68)	(18.43)	(34.39)	(64.42)	(110.77)	(290.81)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INKT MiNK Therapeutics, Inc.	$50.7M	— (loss-making)	—	—	n/m	−32.73% (below 0%: shrinking)	0.00%	0.00%	Compare
LONA LeonaBio, Inc.	$49.8M	— (loss-making)	—	—	n/m	−142.29% (below 0%: shrinking)	0.00%	0.00%
CRBU Caribou Biosciences, Inc.	$49.8M	— (loss-making)	— (loss-making)	−43.79% (below 0%: shrinking)	n/m	−33.16% (below 0%: shrinking)	100.00%	(1,690.39%)	Compare
MREO Mereo BioPharma Group plc - Sponsored ADR	$49.3M	— (loss-making)	— (loss-making)	—	n/m	+21.02% (above 0%: growing)	0.00%	0.00%	Compare
HYPD Hyperion DeFi, Inc.	$49.0M	— (loss-making)	3.6×	+2,333.33% (above 0%: growing)	n/m	+86.82% (above 0%: growing)	100.00%	8,668.63%	Compare
HOWL Werewolf Therapeutics, Inc.	$48.5M	— (loss-making)	— (loss-making)	+256.11% (above 0%: growing)	n/m	+146.46% (above 0%: growing)	100.00%	34.09%	Compare
ELTX Elicio Therapeutics, Inc.	$48.2M	— (loss-making)	— (loss-making)	−55.27% (below 0%: shrinking)	n/m	+8.77% (above 0%: growing)	0.00%	0.00%	Compare
ACET Adicet Bio, Inc.	$48.1M	— (loss-making)	— (loss-making)	+727.73% (above 0%: growing)	n/m	+24.94% (above 0%: growing)	0.00%	0.00%	Compare
KLRS Kalaris Therapeutics Inc.	$47.8M	— (loss-making)	—	—	n/m	+11.91% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$48.7M	—	—	+256.11%	—	+16.47%	0.00%	0.00%

All 614 Biotechnology stocks →

LeonaBio, Inc. (LONA) key facts

Concern: LeonaBio, Inc. reported a net loss of $105.6 million, or a loss of $24.70 per share, for fiscal 2025.
LeonaBio, Inc. (LONA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LONA traded at $5.20, a market capitalization of $49.8 million.
Return on equity was −290.8% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.